As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
10 Analysts have issued a NRX Pharmaceuticals Inc forecast:
10 Analysts have issued a NRX Pharmaceuticals Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -14 -14 |
39%
39%
|
|
| EBIT (Operating Income) EBIT | -14 -14 |
39%
39%
|
|
| Net Profit | -34 -34 |
36%
36%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
| Head office | United States |
| CEO | Jonathan Javitt |
| Founded | 2017 |
| Website | www.nrxpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


